Related Experiment Videos
Affinity-based inhibition of beta-amyloid toxicity
Christopher W Cairo1, Andrea Strzelec, Regina M Murphy
1Department of Chemistry, University of Wisconsin-Madison, Madison, Wisconsin 53706, USA.
Biochemistry
|July 3, 2002
Summary
Researchers developed a new assay to measure how strongly small molecules bind to beta-amyloid peptide. Higher binding affinity correlates with reduced neuronal cell toxicity, supporting targeted drug development for amyloid diseases.
Area of Science:
- Biochemistry
- Neuroscience
- Pharmacology
Background:
- Protein aggregation, particularly beta-amyloid (Aβ) peptide, is central to amyloid diseases.
- Previous studies identified compounds inhibiting Aβ toxicity, but their binding affinity to Aβ was uncharacterized.
Purpose of the Study:
- To develop and validate an assay for measuring small molecule affinities to beta-amyloid peptide.
- To correlate ligand binding affinity with the ability to inhibit Aβ-induced neuronal cell toxicity.
Main Methods:
- Utilized surface plasmon resonance (SPR) with immobilized beta-amyloid peptide at low density.
- Screened low-molecular weight ligands (700-1700 MW) for binding affinity (dissociation constant, K(d)).
- Correlated SPR-measured affinities with results from Aβ neuronal cell toxicity assays.
Main Results:
- Successfully developed an SPR assay to measure small molecule affinities for beta-amyloid peptide.
- Identified low-molecular weight ligands with effective binding affinities (K(d) ≈ 40 μM).
- Demonstrated a direct correlation: higher ligand affinity for beta-amyloid corresponded to greater inhibition of neuronal cell toxicity.
Conclusions:
- Ligands with higher affinity for beta-amyloid peptide are more effective at inhibiting its aggregation and associated cell toxicity.
- The developed SPR assay is a valuable tool for identifying potential therapeutic agents for amyloid diseases.
- Compounds with dissociation constants >100 μM showed no significant cell toxicity inhibition.